Breadcrumb

Breadcrumbs

Press Releases

Search Results

Back to Press Releases
Showing 21 - 30 of 46 results.

You searched for : May 2020 to May 2021.

Daiichi Sankyo Creates New Business Unit to Unify Major Oncology Markets into One Streamlined Organ ...

Daiichi Sankyo Creates New Business Unit to Unify Major Oncology Markets into One Streamlined Organization Dedicated to Patients with Cancer Download the PDF version of Article November 12, 2020...

DESTINY-Breast05 Head-to-Head Phase 3 Trial of ENHERTU® Versus T-DM1 Initiated in Patients with HER ...

DESTINY-Breast05 Head-to-Head Phase 3 Trial of ENHERTU® Versus T-DM1 Initiated in Patients with HER2 Positive Early Breast Cancer at High Risk After Neo-adjuvant Therapy Download the PDF version of...

ENHERTU® Granted Priority Review in the U.S. for Treatment of HER2 Positive Metastatic Gastric Canc ...

ENHERTU® Granted Priority Review in the U.S. for Treatment of HER2 Positive Metastatic Gastric Cancer Download the PDF version of Article October 28, 2020 Only HER2 directed medicine to demonstrate...

Daiichi Sankyo Initiates Phase 1 Trial with Immuno-Oncology Therapy DS-1055 Targeting GARP on Activ ...

Daiichi Sankyo Initiates Phase 1 Trial with Immuno-Oncology Therapy DS-1055 Targeting GARP on Activated Regulatory T Cells   Download the PDF version of Article October 22, 2020 First-in-human...

ENHERTU® Approved in Japan for the Treatment of Patients with HER2 Positive Metastatic Gastric Can ...

ENHERTU® Approved in Japan for the Treatment of Patients with HER2 Positive Metastatic Gastric Cancer Download the PDF version of Article September 25, 2020 ENHERTU is the first and only HER2...

Daiichi Sankyo Announces Late-Breaking Phase 1 Dose Expansion Data for Patritumab Deruxtecan in Pat ...

Daiichi Sankyo Announces Late-Breaking Phase 1 Dose Expansion Data for Patritumab Deruxtecan in Patients with EGFR-Mutated NSCLC at ESMO 2020 Download the PDF version of Article September 18, 2020...

Daiichi Sankyo Initiates Phase 2 Study of Patritumab Deruxtecan in Patients with HER3 Expressing Ad ...

Daiichi Sankyo Initiates Phase 2 Study of Patritumab Deruxtecan in Patients with HER3 Expressing Advanced Colorectal Cancer Download the PDF version of Article September 14, 2020 Phase 2 study to...

Late-Breaking Data for Daiichi Sankyo’s HER3 Directed ADC Patritumab Deruxtecan in EGFR Mutated NSC ...

Late-Breaking Data for Daiichi Sankyo’s HER3 Directed ADC Patritumab Deruxtecan in EGFR Mutated NSCLC to be Presented at 2020 ESMO Annual Meeting    Download the PDF version of Article September...

Daiichi Sankyo Announces Clinical Trial Collaboration with AstraZeneca to Evaluate Patritumab Derux ...

Daiichi Sankyo Announces Clinical Trial Collaboration with AstraZeneca to Evaluate Patritumab Deruxtecan (U3-1402) in Combination with TAGRISSO in EGFR-Mutated Non-Small Cell Lung Cancer Download...

Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for ...

Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi Sankyo’s ADC DS-1062 Download the PDF version of Article July 27, 2020 ...

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...